Biodexa Pharmaceuticals’ (BDRX) stock took a significant dive on Thursday despite positive updates from its ongoing MAGIC-1 study evaluating MTX110 in recurrent glioblastoma (rGBM). While the data suggests potential for a new treatment option, the stock’s reaction highlights investor uncertainty and market volatility.
Biodexa Pharmaceuticals (BDRX) shares surged in after-hours trading following the Nasdaq Hearings Panel’s approval of an extension to meet the $1 minimum bid price requirement. This reprieve grants Biodexa until October 31st to demonstrate compliance, marking a significant development for the clinical-stage biopharmaceutical company.
